OBJECTIVES: The present study examined the relationship between MAGE-A tumor antigens and the efficacy of diamindichloridoplatin (DDP), 5-fluorouracil (5-FU), docetaxel, and paclitaxel for in vitro treatment of head and neck cancer. METHODS: In the present study, five cell lines of human squamous cell carcinomas were treated with DDP (25-400 μM), 5-FU (0.75-12 mM), docetaxel (1.56-25 nM), and paclitaxel (1.56-25 nM) for a period of 24 or 48 h. The efficacy of the agents was observed dynamically using real-time cell analysis. Subsequently, the expression levels of MAGE-A1, MAGE-A5, MAGE-A8, MAGE-A9, MAGE-A11, and MAGE-A12 were determined by quantitative real-time polymerase chain reaction. Chemosensitivity and MAGE-A-expression were correlated by linear regression. RESULTS: The tumor cell lines showed a highly differentiated response to the chemotherapeutic agents. Expression of MAGE-A11 was significantly associated with a poorer response to treatment with DDP, 5-FU, docetaxel, and paclitaxel. Two cell lines, one of which was MAGE-A11-positive, showed a significant and concentration-dependent cisplatin-induced growth spurt during the first 24 h after treatment. MAGE-A5 was connected to a positive effect on treatment with paclitaxel within the first 24 h after application. In association with docetaxel treatment, MAGE-A8 was connected to a poorer susceptibility. CONCLUSIONS: The results describe, for the first time, a correlation between these MAGE-A tumor antigens and the susceptibility of head and neck cancer cells to DDP, 5-FU, docetaxel, and paclitaxel. CLINICAL RELEVANCE: These findings could affect the antineoplastic treatment of patients with MAGE-A11-positive tumors.
OBJECTIVES: The present study examined the relationship between MAGE-A tumor antigens and the efficacy of diamindichloridoplatin (DDP), 5-fluorouracil (5-FU), docetaxel, and paclitaxel for in vitro treatment of head and neck cancer. METHODS: In the present study, five cell lines of humansquamous cell carcinomas were treated with DDP (25-400 μM), 5-FU (0.75-12 mM), docetaxel (1.56-25 nM), and paclitaxel (1.56-25 nM) for a period of 24 or 48 h. The efficacy of the agents was observed dynamically using real-time cell analysis. Subsequently, the expression levels of MAGE-A1, MAGE-A5, MAGE-A8, MAGE-A9, MAGE-A11, and MAGE-A12 were determined by quantitative real-time polymerase chain reaction. Chemosensitivity and MAGE-A-expression were correlated by linear regression. RESULTS: The tumor cell lines showed a highly differentiated response to the chemotherapeutic agents. Expression of MAGE-A11 was significantly associated with a poorer response to treatment with DDP, 5-FU, docetaxel, and paclitaxel. Two cell lines, one of which was MAGE-A11-positive, showed a significant and concentration-dependent cisplatin-induced growth spurt during the first 24 h after treatment. MAGE-A5 was connected to a positive effect on treatment with paclitaxel within the first 24 h after application. In association with docetaxel treatment, MAGE-A8 was connected to a poorer susceptibility. CONCLUSIONS: The results describe, for the first time, a correlation between these MAGE-A tumor antigens and the susceptibility of head and neck cancer cells to DDP, 5-FU, docetaxel, and paclitaxel. CLINICAL RELEVANCE: These findings could affect the antineoplastic treatment of patients with MAGE-A11-positive tumors.
Authors: Martin Monte; Marta Simonatto; Leticia Y Peche; Debora R Bublik; Stefania Gobessi; Marco A Pierotti; Monica Rodolfo; Claudio Schneider Journal: Proc Natl Acad Sci U S A Date: 2006-07-17 Impact factor: 11.205
Authors: Urs D A Müller-Richter; Albert Dowejko; Weiqi Zhou; Torsten E Reichert; Oliver Driemel Journal: Oral Oncol Date: 2007-11-13 Impact factor: 5.337
Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon Journal: Science Date: 1991-12-13 Impact factor: 47.728
Authors: Bing Yang; Sean M O'Herrin; Jianqiang Wu; Shannon Reagan-Shaw; Yongsheng Ma; Kumar M R Bhat; Claudia Gravekamp; Vijayasaradhi Setaluri; Noel Peters; F Michael Hoffmann; Hongzhuang Peng; Alexey V Ivanov; Andrew J G Simpson; B Jack Longley Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701
Authors: Urs D A Müller-Richter; Albert Dowejko; Tobias Reuther; Johannes Kleinheinz; Torsten E Reichert; Oliver Driemel Journal: Head Face Med Date: 2009-04-09 Impact factor: 2.151
Authors: Stefan Hartmann; Norbert Neckel; Axel Seher; Grit Mutzbauer; Roman C Brands; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter Journal: Clin Oral Investig Date: 2015-08-23 Impact factor: 3.573
Authors: Till J Meyer; Stefan Hartmann; Gisela Wohlleben; Muna Brisam; Axel Seher; Alexander C Kübler; Bülent Polat; Urs D A Müller-Richter Journal: Mol Clin Oncol Date: 2018-01-19
Authors: Stefan Hartmann; Muna Brisam; Stephan Rauthe; Oliver Driemel; Roman C Brands; Andreas Rosenwald; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2016-08-03 Impact factor: 2.967
Authors: Sang Tae Noh; Hyoung Shin Lee; Soo Jin Lim; Sung Won Kim; Hee Kyung Chang; Junghwan Oh; Chang-Ho Jeon; Jong Wook Park; Kang Dae Lee Journal: Int J Clin Oncol Date: 2016-05-26 Impact factor: 3.402
Authors: Stefan Hartmann; Leonie Zwick; Mario J J Scheurer; Andreas R Fuchs; Roman C Brands; Axel Seher; Hartmut Böhm; Alexander C Kübler; Urs D A Müller-Richter Journal: Clin Oral Investig Date: 2017-10-15 Impact factor: 3.573
Authors: Stefan Hartmann; Roman C Brands; Nora Küchler; Andreas Fuchs; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2015-06-09 Impact factor: 2.967
Authors: Roman C Brands; Franziska Herbst; Stefan Hartmann; Axel Seher; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter Journal: Clin Oral Investig Date: 2016-02-04 Impact factor: 3.573